Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Xenetic Biosciences Inc (NQ: XBIO )

4.105 +0.092 (+2.30%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenetic Biosciences Inc

< Previous 1 2 Next >
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Via ACCESSWIRE
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Via ACCESSWIRE
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Via ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.